Meanwhile, it remains unclear whether different VEGF pathway inhibitors differ in their effects on BP in cancer patients and how to choose an appropriate treatment regimen by combining the characteristic trends of hypertension induced by VEGF pathway inhibitors. Here, VEGFA is linked to cancer.